Clinical trial · Observational
Screening Tool to Identify the Dominant Pain Mechanism in Cancer Survivors: PainsCan
Development and Validation of a Screening Tool to Identify the Dominant Pain Mechanism in Cancer Survivors With Persistent Pain
NCT03981809CI-TRIAL-00068991PainsCancompletedClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
Development and internal validation of an easy-to-use tool for clinical pain assessment. The tool has to be applicable in any clinical practice and without the need for expensive and complicated hospital tools to identify the source of persistent pain after the treatment of cancer.
Conditions
Conditions (2)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Cancer Pain | — | UNRESOLVED | — |
| Cancer Survivors | — | UNRESOLVED | — |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Diagnostic test ("PainsCan") for the identification of the dominant pain mechanisms in cancer survivers with persistent pain | Diagnostic Test | — | UNRESOLVED |
Design
Arms and outcomes
Arms (0)
[]Primary outcomes (16)
- measure
- Douleur Neuropathic 4 questions (DN4) questionnaire
- timeFrame
- 2 minutes
- description
- Neuropathic pain: pain that arises from a damaged nerve is assessed with a questionnaire (1)
- measure
- Quantitative sensory testing
- timeFrame
- 20 minutes
- description
- Neuropathic pain: pain that arises from a damaged nerve is assessed by measuring thermal thresholds (2)
- measure
- Pain mapping
- timeFrame
- 1 minute
- description
- Neuropathic pain: pain that arises from a damaged nerve is assessed by painting affected areas on a body chart (3)
- measure
- Central Sensitization Inventory (CSI) questionnaire
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Patient treated for primary cancer: breast, prostate, lung/bronchus, colon/rectum, gynecologic (uterus or ovary) * Complete remission * Curative treatment finished * Ongoing hormonal and targeted treatment permitted * Patient experiences pain (NRS minimum 3/10 during the past week) Exclusion Criteria: * Active metastasis * Palliative status * Other type of cancer than mentioned in inclusion criteria * Pregnancy
References
Publications (0)
Data not yet available
No reference posted for this study.